Search Results
Your search for ,WHo matches 20206 pages
Showing 15851 - 15900Smoking Early in Life Is More Strongly Associated with Increased Risk of Breast Cancer
Analyses of data from 73,388 women in the American Cancer Society’s Cancer Prevention Study II (CPS-II) Nutrition Cohort and from a meta-analysis including 14 other studies “support the hypothesis that active smoking increases the risk of breast cancer, especially when smoking begins at an early...
Surgery Delays Longer Than 6 Weeks in Young Women with Breast Cancer Decrease Survival
Delays of more than 6 weeks from time of diagnosis until surgical treatment of breast cancer among young women significantly decreases survival times compared to those with a shorter treatment delay time, according to a study in JAMA Surgery. “This adverse impact on survival was more pronounced in...
Some Stage II/III HER2-positive Tumors May Be Treated with Targeted Therapy without Chemotherapy
Results from a multicenter phase II study of patients with locally advanced HER2-positive breast cancer who receive targeted therapy with trastuzumab (Herceptin) and lapatinib (Tykerb) “support the hypothesis that selected patients with HER2-positive tumors may not need chemotherapy,” investigators ...
Study Clarifies Appropriate Timing of Follow-up Imaging after Benign Breast Biopsies
Follow-up imaging for patients with benign breast biopsies can be safely done at 12 months rather than 6 months, when radiologic and pathologic findings are concordant, according to a study reported at the American Society of Breast Surgeons Annual Meeting in Chicago.1 Current guidelines from the...
Expect Questions from Your Patients
Patients reading or hearing about the updated draft recommendation statement from the U.S. Preventive Services Task Force (USPSTF) on the use of medications to reduce risk for primary breast cancer1 may ask if and how it applies to them. To help answer those questions, the information presented...
Women at Increased Risk for Breast Cancer Should Be Offered Medications to Reduce Risk, Draft Recommendations Advise
Clinicians should engage in shared decision-making with women who are at increased risk of breast cancer about using medications, such as tamoxifen and raloxifene (Evista), to reduce risk, and should offer prescriptions to women considered at low risk for adverse effects from these medications,...
Innovator Award Won by Kenneth Tsai, MD, PhD, for Plan to Map Molecular Path to Skin Cancer
A proposal to examine the cellular journey from normal skin to precancerous lesion to skin cancer earned Kenneth Tsai, MD, PhD, the Sixth Annual Landon Foundation–AACR Innovator Award for Cancer Prevention Research at the American Association for Cancer Research (AACR) Annual Meeting, held recently ...
Francis Crick's Discovery of the Structure of DNA Transformed 20th Century Biologic Sciences
“My Dear Michael, Jim Watson and I have probably made a most important discovery. We have built a model for the structure of des-oxy-ribose-nucleic-acid, called DNA for short.… In other words we think we have found the basic copying mechanism by which life comes from life,” wrote Francis Crick,...
Coping with Tongue Cancer: A Lonely Journey
Thirteen years ago, at just 34 years old, I never expected that my life could be interrupted by cancer. A nonsmoker and nondrinker, I had always practiced a healthy lifestyle and wasn’t concerned initially when what looked like a cold sore popped up on the left side of my tongue. But as several...
Innovative State Program Reduces Colorectal Cancer Disparities, Mortality Rates Among African American Patients
A study analyzing the impact of the Delaware Cancer Consortium, the state’s cancer control program, reports a 41% reduction in colorectal mortality rates for African Americans.1 The recently published study provided analysis on a novel design and approach used to eliminate colorectal cancer...
Focus on the Delaware Society for Clinical Oncology
Although the state of Delaware comprises just 2,489 square miles, giving it an area ranking of 49 out of 50 states, its small size gives its population of nearly 1 million an advantage many larger states do not have: ready access to local politicians to address complex issues such as improving...
Making Prevention and Early Detection of Cancer a Priority
Conquering cancer has been the goal of Bert Vogelstein, MD, since he was a teenager in Baltimore. For more than 3 decades, Dr. Vogelstein, Co-Director of the Ludwig Center for Cancer Genetics and Therapeutics and Investigator of the Howard Hughes Medical Institute at Johns Hopkins Medical...
American Association for Cancer Research CEO Recognized with Prestigious Award from Fox Chase Cancer Center
Margaret Foti, PhD, MD (hc), Chief Executive Officer of the American Association for Cancer Research (AACR), was honored with the 2013 Stanley P. Reimann Honor Award for her deep and far-reaching contributions to cancer science and medicine at a celebration hosted by Fox Chase Cancer Center, held...
Mayo Clinic Genomic Analysis Lends Insight to Prostate Cancer
Mayo Clinic researchers have used next-generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings appeared online recently in the journal Cancer Research.1 Gleason...
Tailored Intervention Protocol for Oral Chemotherapy Adherence Studied
In a study testing the effectiveness of three strategies to improve oral chemotherapy adherence, tailored coaching was beneficial for some patients, reducing barriers to adherence, reported Susan M. Schneider, PhD, RN, AOCN, ACNS-BC, FAAN, Associate Professor and Director of Oncology Nursing...
SIDEBAR: Mara Mogensen Flagherty Lecture
The annual memorial lecture is named for a remarkable patient with cancer who was the “model of survivorship,” sharing her story and helping others cope with the disease. The talk always focuses on a psychosocial aspect of cancer. Since its inception, over 125,000 nurses have attended Mara Mogensen ...
Attention to Patient Concerns Leads to Customized Treatment and Improved Care, Explains Oncology Nurse Researcher
The Mara Mogensen Flagherty Lecture at this year’s 38th Annual Congress of the Oncology Nursing Society in Washington, DC, focused on the importance of listening to and acknowledging the individual stories of patients with cancer and survivors. Once they are adept at listening, clinicians need to...
Smoking Linked to Shorter Disease-free Survival in Stage III Colon Cancer
According to an analysis reported by Amanda Phipps, PhD, MPH, Assistant Professor of Epidemiology at the University of Washington and Assistant Member at Fred Hutchinson Cancer Research Center, Seattle, and colleagues in the Journal of Clinical Oncology, patients with stage III colon cancer who...
HIV Infection Does Not Adversely Affect Outcomes of Liver Transplantation for Hepatocellular Carcinoma
Liver transplantation for hepatocellular carcinoma is feasible for HIV-infected patients, with no differences in post-transplant survival or hepatocellular carcinoma recurrence rates compared with liver transplantation for hepatocellular carcinoma in HIV-uninfected patients. The study, published in ...
Low-dose CT Detects Twice as Many Early-stage Lung Cancers as Chest X-ray, According to Additional NLST Results
Results of the first of three planned annual screening examinations from the National Lung Screening Trial (NLST) were recently published and physicians may now have more information to share with their patients about the benefits and risks of low-dose computed tomography lung cancer screening.1...
No Difference in Overall Survival with Axitinib or Sorafenib in Second-line Treatment for Advanced Renal Cell Carcinoma
The phase III open-label AXIS trial comparing axitinib (Inlyta) vs sorafenib (Nexavar) as second-line treatment for metastatic renal cell carcinoma showed significantly prolonged independent radiology committee–assessed progression-free survival with axitinib treatment (hazard ratio [HR] = 0.665, P ...
Peregrine Pharmaceuticals Reaches Agreement with FDA on Phase III Trial Design for Bavituximab in NSCLC
Peregrine Pharmaceuticals recently announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a phase III registration trial design of the company’s lead clinical immunotherapeutic candidate bavituximab in second-line non–small cell lung cancer (NSCLC). The trial...
Meta-analysis Slightly Favors Platinum-based First-line Treatment in Patients with Advanced NSCLC
Several meta-analyses conducted in the past have suggested that survival of patients with advanced non–small cell lung cancer (NSCLC) is improved if first-line chemotherapy includes platinum derivatives. Results from a new meta-analysis of randomized clinical trials show that platinum-based...
Simultaneous EGFR Mutations and HER2 Gene Amplifications in Large Series of Patients with Non–Small Cell Lung Cancer
In a molecular profile analysis of 2,271 cases of non–small cell lung cancer (NSCLC), EGFR was mutated in 12% and KRAS in 32% of cases. HER2 gene amplification was confirmed as a rare event in NSCLC (4%). Coexistence of HER2 gene amplification and EGFR mutation was identified in three cases, while...
CancerProgress.Net Patient and Advocate Video Series Highlights Value and Impact of Cancer Research
“I’ve been living with melanoma for 7 years.” That’s a statement that, at the outset of her diagnosis, Joanne Maricle would have found surprising. Yet Joanne, who is featured in a video that is part of a new Patient and Advocate Video Series on ASCO’s CancerProgress.Net website, is able to lay...
ASCO Publishes New Conflict of Interest Policy
ASCO has released its new conflict of interest policy, ASCO Policy for Relationships With Companies, which updates its earlier policy in key ways that are designed to increase transparency in relationships with commercial interests. Comprehensive Framework The new policy establishes a more...
Best of ASCO® Meetings Provide Intimate Access to Latest Research
Aiming to facilitate widespread dissemination of practice-changing research, ASCO offers the Best of ASCO® Meetings, which condense the most cutting-edge science and education from the ASCO Annual Meeting into a 2-day program. The smaller size of these meetings, compared to the Annual Meeting,...
Transforming Grand Rounds into Chartrounds: Technology and the Improving Cancer Care Grant Advance Patient Care
When Patricia Hardenbergh, MD, moved from her academic position as a breast radiation oncologist at Duke University to a small, rural practice in Edwards, Colorado, she realized that being a community oncologist was a very different experience. She was an expert in treating breast cancer and also...
Geriatric Factors Predict Severe Toxicity in Elderly Patients on First-line Treatment for Metastatic Colorectal Cancer
Elderly patients differ with respect to tolerance of therapy for colorectal cancer. In a study reported in Journal of Clinical Oncology, Thomas Aparicio, MD, PhD, of the University of Paris, and colleagues analyzed geriatric factors for potential association with severe toxicity, dose-intensity...
John P. Leonard, MD, Leads NCI's Alliance for Clinical Trials in Oncology Lymphoma Committee
John P. Leonard, MD, a hematology and oncology expert specializing in the treatment of lymphomas at Weill Cornell Medical College, has been named Chair of the Lymphoma Committee for the National Cancer Institute (NCI)-sponsored group, the Alliance for Clinical Trials in Oncology. Dr. Leonard is the ...
Determining the Best Diet for Patients with Cancer
How much does diet and body weight influence the effectiveness of cancer treatment and reduce the risk of cancer recurrence? What is the optimal diet for patients with cancer and survivors to follow? There are currently no hard and fast rules, but some dietary clues are starting to emerge. Search...
A New Center for Lymphoid Malignancies Aims to Provide Precision Patient Care
In January, New York-Presbyterian Hospital/Columbia University Medical Center opened the Center for Lymphoid Malignancies, a 3,700 square foot outpatient clinic, in the heart of Midtown Manhattan. The Center is solely focused on the treatment of all forms of Hodgkin and non-Hodgkin lymphoma,...
Intensified Liposomal Daunorubicin May Offer High Survival Rates without Added Cardiotoxicity for Children with Leukemia
Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at an intensified dose during initial treatment may result in high survival rates without causing any added heart toxicity, according to the results of a study published online in Blood.1 Acute...
Postinduction Dexamethasone and Individualized Dosing of Asparaginase Improve Outcome in Pediatric ALL
Findings from the Dana-Farber Cancer Institute ALL Consortium Protocol 00-01, recently reported by Lynda M. Vrooman, MD, Dana-Farber Cancer Institute, and colleagues in Journal of Clinical Oncology, indicate that postinduction dexamethasone and individualized dosing of Escherichia coli–derived...
Cancer Organizations Recognize Sen. Shelby and Rep. DeLauro for Their Commitment to the Fight against Cancer
Sen. Richard Shelby (R-AL) and Rep. Rosa DeLauro (D-CT) were recognized recently by the American Society of Clinical Oncology, the American Association for Cancer Research, the Association of American Cancer Institutes, and Friends of Cancer Research for their outstanding commitment to cancer...
Double the Mastectomy, Double the Complications
A retrospective analysis of a large surgical database has documented that bilateral mastectomy is associated with a doubling in complication rates, compared with unilateral mastectomy. Researchers reported the findings at the 14th Annual Meeting of the American Society of Breast Surgeons in...
Pulmonary Metastasectomy in Patients with Colorectal Cancer
The largest-to-date and only prospective Spanish series of 549 patients who underwent surgical resection of lung metastases from colorectal carcinoma demonstrated a good postoperative recovery from the procedure. A further analysis on morbidity, the correlation between imaging studies and...
Expert Point of View: Alison Freifeld, MD
The EORTC Infectious Diseases Group Trial XV “is a long-awaited study because it finally is an investigation of outpatient management of low-risk fever and neutropenia in a large number of patients,” Alison Freifeld, MD, of the University of Nebraska Medical Center in Omaha, commented in an...
Once-daily Moxifloxacin for Low-risk Patients with Febrile Neutropenia
Once-daily oral moxifloxacin works at least as well as twice-daily oral ciprofloxacin plus amoxicillin–clavulanic acid when it comes to treating febrile neutropenia in patients who are at low risk for complications, according to a randomized, double-blind trial reported in the Journal of Clinical...
SIDEBAR: Notes from a Death with Dignity Program
Participation in the Seattle Cancer Care Alliance Death with Dignity program reflects concerns about autonomy, dignity, and functional status rather than disease-related symptoms or depression. The Death with Dignity program “both allows patients with cancer who wish to consider this option to do...
Death with Dignity Program at Seattle Cancer Care Alliance
After passage of the Washington Death with Dignity Act in November 2008, the Seattle Cancer Care Alliance—the site of outpatient care for patients with cancer from Fred Hutchinson–University of Washington Cancer Consortium—developed a Death with Dignity program. The program is adapted from existing ...
SIDEBAR: Physician-assisted Suicide
Readers’ comments extracted from www.nejm.org To force people to live simply because we possess the technology to do so does not speak to either the ethics or the morality of such a decision. Suffering has existential dimensions. Symptoms can be treated with greatest chance. My grandfather...
Expert Point of View: Andrew D. Zelenetz, MD, PhD
In a separate interview, Andrew D. Zelenetz, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan-Kettering Cancer Center in New York, said that he found the relapse rate of 20% observed in this study to be quite low, and he wanted to know the characteristics of the 537 patients included in the ...
Study Questions Routine Use of Imaging after Treatment for Diffuse Large B-cell Lymphoma
Most relapses following treatment for diffuse large B-cell lymphoma are detected by abnormalities on physical exam, lab tests, and symptoms—not by routine imaging, according to a study presented at the ASCO Annual Meeting.1 In fact, in a prospective study assessing post-treatment outcomes of...
Potent Activity Shown for First-in-class PI3K-delta Inhibitor in Chronic Lymphocytic Leukemia
Heavily pretreated patients with chronic lymphocytic leukemia (CLL) responded robustly to the first-in-class small-molecule inhibitor idelalisib (formerly GS1101), in a phase I dose-finding study reported in a press briefing prior to the 2013 ASCO Annual Meeting.1 Idelalisib, a specific inhibitor...
Impressive Results Shown for Immune Checkpoint Inhibitors: Anti-PD1 and Anti-PD-L1 Antibodies
Antibody-mediated blockade of the programmed death 1 protein (PD-1) and its ligand (PD-L1) resulted in potent and durable tumor regression and prolonged stabilization of disease in patients with advanced solid tumors, according to early data on these drugs presented at the 2013 ASCO Annual Meeting. ...
One Cancer Center's Approach to Death with Dignity
In November 2008, the Washington State legislature passed the Washington Death with Dignity Act allowing patients with a terminal diagnosis and less than 6 months to live to request and self-administer lethal medication. After considerable internal debate, our cancer center elected to develop a...
Caring for the Whole Patient Both during Active Treatment and at End of Life
Despite studies showing that a majority of patients prefer to die at home rather than in an institutional setting,1 in many parts of the country, over 30% die in nursing homes and over 50% die in hospitals, according to Ira Byock, MD, Director of Palliative Medicine, Dartmouth-Hitchcock Medical...
For Renowned Researcher, Seeing Basic Science Turn into Promising Therapies Is the 'Holy Grail' of Oncology
“From bench to bedside” is a phrase that captures the essence of modern oncology: Researchers at the bench seek to solve the biologic puzzles of cancer that can translate into the development of therapeutics delivered at the bedside. Owen N. Witte, MD, has spent most of his career as a basic bench...
Innovative Leader in Oncology Is Committed to Tackling the Most Critical Issues in Managed Care
“I’m a Nebraskan,” said Lee N. Newcomer, MD, MHA, a leader in the oncology community who is well known for his innovative efforts to align physician payment and quality of care in ways that will best configure to the rapidly changing health-care environment. Speaking in the flat vowels and neutral...
